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Abstract: Mycophenolate mofetil (MMF) interacts with purine metabolism and possibly with the 
expression of adhesion molecules. In the present study, we analysed the expression of these molecules 
in transplanted kidney allografts treated with RS LBNF1 kidneys were orthotopically transplanted into 
Lewis rats and either treated with RS (20 mg/kg/day) or vehicle. Rats were harvested 3, 5 and 7 days 
following transplantation. For binding studies, fresh-frozen sections of transplanted kidneys were incu- 
bated with lymph node lymphocytes (LNL) derived from transplanted rats. Additionally, immunohistology 
was performed with various monoclonal antibodies. In general, MMF resulted in better preservation of
graft structure by 7 days. Cellular infiltration and tubular atrophy were less pronounced. At day 3, macro- 
phages were diminished in MMF-treated animals to a high extent, while the number of T ceils was almost 
identical to that of controls. In addition, the number of cells positive for MHC class II and LFA-1 was 
reduced in the MMF-treated animals. These findings correlated with the binding results. Three days fol- 
lowing engraftment, LNL bound to MMF-treated kidneys to a lesser extent compared to controls. In 
conclusion, MMF resulted in a markedly reduced leucocytic infiltrate, presumably based on a reduced 
expression of lymphocytic adhesion molecules and an interaction with macrophages. 
Introduction 
Much has been learned regarding the process of acute rejec- 
tion. Recently, interest has focused on the role of adhesion 
molecules in this process. These molecules play an important 
role during extravasation, antigen presentation and prolifer- 
ation of lymphocytes.~'2 Upregulation of adhesion molecules 
may be caused by cytokine-elaborated vents such as surgical 
manipulations, ischemia, cooling and reperfusion. The pres- 
ence of cytokines increases the expression of several critical 
molecules on human renal tubular cells, including ICAM-1 
and MHC class I and class II.~ Mycophenolate mofetil (MMF), 
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on the other hand, is a drug known to act beneficially during 
acute rejection. 3'4 In vitro experiments indicated its potential 
to inhibit the proliferation of lymphocytes and to reduce the 
upregulation of adhesion molecules on several cell types. 5-8 
Objective 
The goal of our study was to elucidate to what extent the 
beneficial effect of MMF on the incidence of acute rejection 
is based on a reduced expression of adhesion molecules or 
other mechanisms. 
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Materials and methods 
Animals 
Naive male 200-250 g inbred rats (Harlan Sprague-Dawley, 
Indianapolis, IN) were used throughout the experiments: 
Lewis (LEW) rats acted as graft recipients, Lewis/Brown Nor- 
way (LBNF1) as donors. 
Kidney grafting 
The left donor kidney was removed, cooled and positioned 
anatomically into the host. Donor and recipient renal artery, 
vein and ureter were then anastomosed end-to-end with 10-0 
prolene sutures. No ureteral stent was used. Recipients (n = 30) 
were either treated with MMF (20 mg/kg/day) or with vehicle. 
Tissue preparation 
Organs and tissues were harvested 3, 5 and 7 days alter trans- 
plantation, snap frozen in liquid nitrogen and stored at -70°C, 
or fixed in formalin or acid formalin for hematoxylin~eosin 
staining. 
Antibodies 
Monoclonal antibodies (mAbs) to adhesion molecules 
included those directed against LFA-Ic, (WT.l) ,  ICAM-1 
(1A29) (Prof. Miyasaka, Tokyo) and VCAM-1 (Genzyme, 
Boston). Antibodies against T cells (CD5/OX- 19), 
monocytes/macrophages tED-l) ,  MHC class II (OX-3) and 
neutrophils (MOM/3FI2/F2)  were obtained from Sera-Lab 
(Accurate Chemicals, Westbury, NY). 
Immunohistology 
Cryostat sections of frozen tissues were stained with 1A29, 
WT. l, ED- 1, MOM/3F 12/F2, OX-3, W3/25, and OX- 19 using 
the alkaline phosphatase/antialkaline phosphatase (APAAP) 
method. Stained cells were then counted with an ocular grid 
(x600, >30 fields counted per specimen); tissue staining was 
evaluated on a scale of 1-4. 
Preparation of cell suspensions 
Lymph node lymphocytes (LNL) from cervical and axillary 
lymph nodes were minced through stainless steel mesh, sus- 
pended and washed with phosphate-buffered saline. Cell prep- 
arations were evaluated using fluorescence staining with 
appropriate antibodies and discarded if purification was 
<95%.  
Table 1 Effects of MMF and vehicle treatment 
Binding assay 
For binding studies, a modified Stamper-Woodruff  assay was 
used. s Aliquots (7 × l0 s cells) of LNL from grafted Lewis rats 
treated with or without MMF were incubated for 30 in at 64 
rpm at 25°C with snap-frozen sections of kidney allografts 
serially harvested from the same animals: LNL from naive 
Lewis rats served as additional controls. The preparations were 
fixed in a 1.5% glutaraldehyde solution and counterstained 
with hematoxylin. Cells, bound to the allografts were then 
counted and described as cells per field of view. All exper- 
iments were performed in quadruplicate. Only sections with 
the tissue structure unaltered and intact at the time of evalu- 
ation were used. 
Statistics 
Results were evaluated using Student's t-test. 
Results 
Transplanted kidneys of control animals were almost com- 
pletely destroyed 10 days after transplantation. On the other 
hand, only a few necrotic areas and a small number of atrophic 
tubules were observed in kidneys of MMF-treated rats at that 
time. These results correlated with the extent of cellular infil- 
tration. While in the MMF kidneys macrophages and lympho- 
cytes were found at 10 days postoperation, only minimal cellu- 
lar infiltration was observed in the almost completely 
destroyed kidneys of the control animals (Table 1). 
The pattern of leucocyte infiltration differed between MMF 
and vehicle-treated animals. Three days postoperation, infil- 
tration of neutrophils (MMF: 1.2 ± 0.3 vs 3.7 ± 0.1 in controls, 
p < 0.01) and macrophages (MMF: 16 _+ 5.8 vs 45.3 ± 17.2 in 
controls, p < 0.01) was considerably lower compared to 
MMF-treated animals, whereas the number of lymphocytes 
(MMF: 28.4 ± 11.1 vs. 28.4 ± 11 in controls) was almost ident- 
ical. In both groups cellular infiltration peaked 5 days postop- 
eration. However, the number of infiltrating leucocytes was 
markedly reduced in MMF-treated animals. Furthermore, 
while the number of macrophages deceased in control animals 
in parallel to the degree of destruction and fibrosis, it remained 
almost constant in MMF-treated animals. 
Leucocytes positive for LFA-Ic~ were significantly reduced 
in grafts treated with MMF compared to control animals on 
days 3 and 5. Surprisingly, ICAM-I and VCAM-I  expression 
Days Group Lymphocytes Monocytes/ Neutrophils 
post-transplant (c/f v) macrophages (c/f;') 
(c/fv) 
MHC II ICAM-P' LFA-I(x 
positive positive 
leucocytes leucocytes 
(c/fv) (c/fv) 
VCAM-I " 
3 MMF 28.4+11.1 16+5.8" 1.2+0.3 18.5+5.7 1.3+0.3 4.8+0.8 
3 Vehicle 28.4+ 11 45.3+ 17 .2  3.7+0.1 25.2+7.5 1.5+0.4 7.4+0.7 
5 MMF 27.2+6.3 67.8+5.3 1.9+(/.3 46.2+2.1 3+0.4 14.1 +6.3 
5 Vehicle 56.4 + 4.2 73.2 + 7 2 + 0.2 43.8 + 4 3.3 + 0.1 19.9 + 4.4 
7 MMF 13.5+2.8 63.5 + 6.1 1.9+0.4 36.8+4.9 3.5+0.2 10.4+3.5 
7 Vehicle 2.4 + 0.9 37. l + 1.5 6. I + 3 48.6 + 7.8 3.5 + 0.2 6. I + 4.3 
0.3+0.1 
0.3+0.1 
0.3 + 0.1 
0.5 + 0.2 
0.3+0.1 
0.1 +0.1 
Values are given as mean + standard eviation. 
"Graded by visual intensity on a scale 0 4 (0, no staining; 4. extremely strong staining). 
* p < 0.01. 
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was almost identical in both groups. There was, however, a 
difference in MHC II expression. The number of MHC II posi- 
tive infiltrating cells was reduced in the MMF group at day 3 
postoperation a d continued on the days 5 and 7. This tend- 
ency, however, was not statistically significant. Taken 
together, adhesion molecules on endothelial cells were affec- 
ted by MMF treatment, whereas those on lymphocytes were 
reduced. 
Thus far, the results of our binding studies revealed similar 
results. On days 3 and 5, in particular, the number of LNL 
derived from both naive and recipient animals was lower in 
the MMF-treated groups. This effect proved to be statistically 
significant in those grafts incubated with lymphocytes derived 
from the same animal. In these cases, MMF significantly ow- 
ered the number of lymphocytes bound to transplanted grafts 
on days 3 and 5 postoperation (p < 0.01) (Table 2). While 
there was a tendency towards lower numbers of lymphocytes 
derived from naive rats bound to MMF-treated grafts com- 
pared to grafts treated with vehicle, the results were only sig- 
nificant for day 5 postoperation. Overall, the number of naive 
lymphocytes bound to transplanted grafts treated with vehicle 
was lower than that of lymphocytes derived from transplanted 
animals. In contrast, lymphocytes derived from MMF-treated 
animals bound to a lower degree than naive lymphocytes to 
MMF-treated grafts. 
We evaluated particularly the binding to the different kidney 
structures, i.e. interstitial nd tubular epithelial cells and endo- 
thelial cells. Although there was a difference regarding the 
number of lymphocytes bound to the kidneys as a whole, the 
relative distribution remained the same in all groups. Lympho- 
cyte binding was most prominent in and around tubules, fol- 
lowed by binding to endothelial vessel walls, venules in parti- 
cular. Binding to interstitial structures tended to increase only 
in parallel with interstitial fibrosis and sclerosis. Lymphocyte 
binding to glomerular structures was insignificant. 
Discuss ion 
MMF is capable of preventing or reducing the incidence of 
acute and chronic rejection in in vivo experiments. 3'9'm This 
was demonstrated for acute rejection episodes not only in ani- 
mal experiments but also in human kidney transplantation. 4 I  
vitro experiments identified an antiproliferative effect of 
MMF, based on interaction with inosine monophosphate 
dehydrogenase--an enzyme involved in purine synthesis--and 
the expression of mannose-rich glycoprotines. 7'8As adhesion 
Table 2 Results of the binding assay of lymph node lymphocytes (LNL) 
derived from grafted and naive Lewis rats 
Day 
post- 
operation 
Animals treated with: a Grafts treated with: b 
MMF vehicle MMF vehicle 
3 184+_37 387_+45** 243_+26 283+34 
5 262+_21 480_+59** 386_+33 443_+43 
7 211_+19 234_+33 223_+24 301_+53" 
Cells bound to grafted kidneys expressed ascells per field of view (c/fv). 
aLNL derived from hosts. 
bLNL derived from naive Lewis rats. 
*p < 0.05; **p < 0.01. 
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molecules are among these mannose-containing glycoproteins, 
it was not unexpected that MMF additionally affected the 
expression of adhesion molecules. 8 Given that adhesion mol- 
ecules are important for the infiltration of leucocytes into 
transplanted organs,' we investigated whether this inhibition 
of adhesion molecule xpression influences organ transplan- 
tation in vivo. 
Our results were twofold. First, we could demonstrate he 
beneficial effect of MMF upon acute rejection. Grafts in ani- 
mals treated with MMF survived longer than those treated with 
vehicle. This can be attributed to a markedly reduced cellular 
infiltrate. Most interesting was the striking reduction of macro- 
phages and the comparatively lower reduction of lymphocytes, 
especially at day 3 postoperation. This implies a significant 
influence upon macrophages which has not been demonstrated 
previously, although others observed similar findings in other 
models of animal transplantation. 1' At 3 days postoperation, 
the start of lymphocytic infiltration, the numbers of lympho- 
cytes observed in the graft were almost identical between 
MMF- and vehicle-treated rats. This is surprising as the num- 
ber of lymphocytes bound to the graft at that time differed 
markedly among these groups. Lymphocyte binding to MMF- 
treated grafts was significantly lower than in vehicle-treated 
rats. Additionally, the number of lymphocytes derived from 
naive animals that bound to MMF-treated animals was higher 
than that derived from MMF-treated animals. Taken together 
with the lack of difference between MMF- and vehicle-treated 
grafts regarding the expression of ICAM-1 and VCAM-1, 
these findings imply a primary site of action on lymphocytes 
and not on endothelial or epithelial cells, as has been suggested 
by previous works. 7'8 These findings are additionally supported 
by the reduced expression of LFA- 1 on lymphocytes in MMF- 
treated animals compared to placebo-treated ones. 
On the other hand, at day 3 postoperation, binding of naive 
lymphocytes to endothelial cells of allografted kidneys treated 
with MMF was markedly reduced compared to control ani- 
mals, while the number of lymphocytes in the grafts was 
almost identical. Although VLA-4 is suspected to be respon- 
sible for this lymphocyte adhesion, our results do not support 
this hypothesis, because the expression of VCAM-1, the ligand 
of VLA-4, was not reduced in our experiments. Based on these 
findings we would hypothesize that fewer lymphocytes enter 
the graft of MMF-treated hosts, but remain in the graft for a 
longer time, thus prolonging recirculation tolymph nodes. The 
interaction between macrophages and lymphocytes may be 
important in this setting. Previous studies reported a variety 
of chemokines and cytokines promoting the interaction of 
macrophages and lymphocytes, inducing the production of 
extracellular matrix proteins along which lymphocytes are 
directed. L,2,, 3 The lack of these molecules, a result of the small 
number of macrophages inside the grafts, may thus decrease 
the motility of lymphocytes once they have entered the graft. 
This would also explain the beneficial effects of MMF on 
chronic rejection and arterial intimal thickening produced by 
mechanical injury9 °''3 Taken together, MMF seems to interact 
primarily with expression of adhesion molecules on lympho- 
cytes and not on endothelial cells. If there is an additional 
effect on macrophages, there could be a potential for this drug 
to influence chronic rejection as has been suggested by pre- 
vious studies. '° 
In conclusion, the beneficial effects of MMF on the process 
of acute kidney allograft rejection result from an inhibition of 
leucocyte infiltration into the transplanted kidney. These 
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effects are due at least in part to a reduction of lymphocyte 
adhesion to endothelial cells. Whether the reduced adhesion 
is based solely on the inhibition of lymphocyte activation and 
the resulting reduced secretion of inflammatory substances 
such as cytokines, or whether there is an additional direcl 
effect on macrophages, remains elusive. 
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